Syndax is a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease. Self-described commitment to scientific excellence.

Syndax

Domain Not Resolving

Google Font API

Google

Google Cloud

jQuery CDN

Vimeo

Google Cloud Global Multi-Region

Mobile Optimized

New Relic

Drupal

Chief Business Officer

Anjali Ganguli

Briggs Morrison

President and Chief Operating Officer

Michael Metzger

Chief Medical Officer

Michael Meyers

Chief Scientific Officer

Peter Ordentlich

Chief Commercial Officer (CCO)

Steve Sabus

Vice President of Clinical Operations

Barbara Schaeffler

Vice President, Pharmaceutical Development & Manufacturing

Bret Shirley

Vice President, Head of Drug Safety and Pharmacovigilance

Dennis O'Brien

Vice President

Jerry McGeehan

Dennis Podlesak

Kim P. Kamdar

Artthur M. Pappas

Pierre Legault

Keith A Katkin

Jennifer Jarrett

William Meury

Chief Scientific Officer and Founder

Keith A. Goldan

Chief Financial Officer

Daphne Karydas

Matthew G. Nerney

Kate Madigan

Steven Closter

Chief Commercial Officer

President, Head of Research & Development

Luke Albrecht

General Counsel and Secretary

Health Care Companies that Exited (Top 10K)

Pharmaceutical Companies that Exited

Massachusetts Companies (Top 10K)

Hedge Fund Funded Companies

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.

Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Post-IPO Equity - Syndax Pharmaceuticals

AI Life Sciences Investments LLC

Biotechnology Value Fund

Boxer Capital

Hercules Capital

Post-IPO Debt - Syndax Pharmaceuticals

Delos Capital

Fidelity

Series C - Syndax Pharmaceuticals

Debt Financing - Syndax Pharmaceuticals

Computer and Software Services and Scientific Services

Waltham

Massachusetts

United States

North America

Syndax Pharmaceuticals

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Citigroup Maintains Buy on Syndax Pharmaceuti...

Syndax Pharmaceuticals target cut by BofA on FDA delay

Stifel cuts Syndax Pharma target on FDA delay, retains Buy tag

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Syndax: Gearing Up For Launches (NASDAQ:SNDX)

Stifel raises Syndax Pharma stock target on drug approval optimism By Investing.com

Hong Kong

Asia

India

Malaysia

Italy

Europe

HTML5

Gravity Forms

jQuery

Microsoft Outlook

Cloudflare CDN

Modernizr

Office 365

Google Analytics

Google Tag Manager

Adobe Fonts

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Syndax Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 13, 2024 8:56 AM	e6491794
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 13, 2024 8:56 AM	4c83e768
crunchbase trigger	general	Oct 31, 2024 9:55 AM	59594af1
crunchbase profile	general	Oct 31, 2024 11:37 AM	b5b5e9be
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	a5a66957
peers	general	Sep 13, 2024 8:56 AM	fcfc54c9
news basic	general	Sep 13, 2024 8:56 AM	e1ad3370
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SYNDAX

Syndax

Last Close

15.60

22/11 21:00

Market Cap

1.93B

Beta: -

Volume Today

1.44M

Avg: -